Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Synta leaps on Phase II ENCHANT-1 data

Shares of Synta Pharmaceuticals Corp. (NASDAQ:SNTA) jumped $2.09 (41%) to $7.15 on Monday after the company said it

Read the full 189 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE